Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have been shown to act selectively on gene expression, and are potent inducers of growth arrest, differentiation and apoptosis in various types of cancers in vitro and in vivo. This study aimed to elucidate the anti-tumor effects and molecular mechanisms of SAHA on the aggressive phenotypes of ovarian carcinoma. Two pairs of cell lines (SKOV3 and SKOV3/DDP; HO8910 and HO8910-PM) were exposed to SAHA treatment, and the effects on acetyl-Histone H3 and H4 expression levels were analyzed and compared against the aggressive behaviors of ovarian carcinoma. Our results showed that SAHA suppressed proliferation in both a concentration- and time-dependent manner...
[[abstract]]Suberoylanilide hydroxamic acid (SAHA), a potent histone deacetylase (HDAC) inhibitor, h...
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare but extremely lethal malign...
Objective: Tamoxifen is currently used for the treatment of estrogen receptor-positive breast cancer...
Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have been sh...
<div><p>Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have...
Objective. Our study analyzed the effects of HDAC inhibitor SAHA treatment on gene expressions of Ch...
Anti-estrogens are the current endocrine therapy of choice in the treatment of estrogen receptor (ER...
SAHA (suberoylanilide hydroxamic acid or vorinostat) is the first nonselective histone deacetylase (...
Gene expression is often altered by epigenetic modifications that can significantly influence the gr...
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, yet effective therapeut...
Histone deacetylase inhibitors (HDACIs) activate genes that promote cell cycle arrest and apoptosis ...
Histone deacetylase inhibitors (HDACIs) activate genes that promote cell cycle arrest and apoptosis ...
The emergence of tumour recurrence and resistance limits the survival rate for most tumour-bearing p...
[[abstract]]Suberoylanilide hydroxamic acid (SAHA), a potent histone deacetylase (HDAC) inhibitor, h...
[[abstract]]Triple-negative breast cancer (TNBC), defined by the absence of an estrogen receptor, pr...
[[abstract]]Suberoylanilide hydroxamic acid (SAHA), a potent histone deacetylase (HDAC) inhibitor, h...
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare but extremely lethal malign...
Objective: Tamoxifen is currently used for the treatment of estrogen receptor-positive breast cancer...
Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have been sh...
<div><p>Histone deacetylase inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA), have...
Objective. Our study analyzed the effects of HDAC inhibitor SAHA treatment on gene expressions of Ch...
Anti-estrogens are the current endocrine therapy of choice in the treatment of estrogen receptor (ER...
SAHA (suberoylanilide hydroxamic acid or vorinostat) is the first nonselective histone deacetylase (...
Gene expression is often altered by epigenetic modifications that can significantly influence the gr...
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, yet effective therapeut...
Histone deacetylase inhibitors (HDACIs) activate genes that promote cell cycle arrest and apoptosis ...
Histone deacetylase inhibitors (HDACIs) activate genes that promote cell cycle arrest and apoptosis ...
The emergence of tumour recurrence and resistance limits the survival rate for most tumour-bearing p...
[[abstract]]Suberoylanilide hydroxamic acid (SAHA), a potent histone deacetylase (HDAC) inhibitor, h...
[[abstract]]Triple-negative breast cancer (TNBC), defined by the absence of an estrogen receptor, pr...
[[abstract]]Suberoylanilide hydroxamic acid (SAHA), a potent histone deacetylase (HDAC) inhibitor, h...
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare but extremely lethal malign...
Objective: Tamoxifen is currently used for the treatment of estrogen receptor-positive breast cancer...